Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is
triggered by inflammatory attack of the CNS. As yet there is no satisfactory treatment. Using …

Chronic relapsing experimental allergic encephalomyelitis (CREAE) is an autoimmune
model of multiple sclerosis 1 . Although both these diseases are typified by relapsing-remitting …

Research of the cannabinoid system has many similarities with that of the opioid system. In
both instances, studies into drug-producing plants led to the discovery of an endogenous …

Spasticity is a complicating sign in multiple sclerosis that also develops in a model of
chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas …

The cannabinoid system is immunomodulatory and has been targeted as a treatment for the
central nervous system (CNS) autoimmune disease multiple sclerosis. Using an animal …

Increasing evidence suggests that some cannabinoids mediate their effects independently
of the known cannabinoid CB 1 and CB 2 receptors. Two recently published patents indicate …

Although most autoimmune diseases are considered to be CD4 T cell- or antibody-mediated,
many respond to CD20-depleting antibodies that have limited influence on CD4 and …

Blood-brain barrier (BBB) dysfunction is a hallmark of neurological conditions such as
multiple sclerosis (MS) and stroke. However, the molecular mechanisms underlying …

Although multiple sclerosis (MS) is considered to be a CD4, Th17-mediated autoimmune
disease, supportive evidence is perhaps circumstantial, often based on animal studies, and is …

Neuroinflammatory diseases, such as multiple sclerosis (MS), result from aberrant leucocyte
traffic into the central nervous system (CNS). To breach the specialized blood-brain barrier, …